- Research article
- Open Access
Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines
BMC Cancer volume 17, Article number: 49 (2017)
Combination drug therapy appears a promising approach to overcome drug resistance and reduce drug-related toxicities in ovarian cancer treatments. In this in vitro study, we evaluated the antitumor efficacy of cisplatin in combination with Bithionol (BT) against a panel of ovarian cancer cell lines with special focus on cisplatin-sensitive and cisplatin-resistant cell lines. The primary objectives of this study are to determine the nature of the interactions between BT and cisplatin and to understand the mechanism(s) of action of BT-cisplatin combination.
The cytotoxic effects of drugs either alone or in combination were evaluated using presto-blue assay. Cellular reactive oxygen species were measured by flow cytometry. Immunoblot analysis was carried out to investigate changes in levels of cleaved PARP, XIAP, bcl-2, bcl-xL, p21 and p27. Luminescent and colorimetric assays were used to test caspases 3/7 and ATX activity.
The efficacy of the BT-cisplatin combination depends upon the cell type and concentrations of cisplatin and BT. In cisplatin-sensitive cell lines, BT and cisplatin were mostly antagonistic except when used at low concentrations, where synergy was observed. In contrast, in cisplatin-resistant cells, BT-cisplatin combination treatment displayed synergistic effects at most of the drug ratios/concentrations. Our results further revealed that the synergistic interaction was linked to increased reactive oxygen species generation and apoptosis. Enhanced apoptosis was correlated with loss of pro-survival factors (XIAP, bcl-2, bcl-xL), expression of pro-apoptotic markers (caspases 3/7, PARP cleavage) and enhanced cell cycle regulators p21 and p27.
In cisplatin-resistant cell lines, BT potentiated cisplatin-induced cytotoxicity at most drug ratios via enhanced ROS generation and modulation of key regulators of apoptosis. Low doses of BT and cisplatin enhanced efficiency of cisplatin treatment in all the ovarian cancer cell lines tested. Our results suggest that novel combinations such as BT and cisplatin might be an attractive therapeutic approach to enhance ovarian cancer chemosensitivity. Combining low doses of cisplatin with subtherapeutic doses of BT can ultimately lead to the development of an innovative combination therapy to reduce/prevent the side effects normally occurring when high doses of cisplatin are administered.
Drug resistance to currently used chemotherapies is the fundamental cause of recurrence and poor overall survival in ovarian cancer patients [1–3]. Between 70 and 80% of ovarian cancer patients show an initial positive response to the standard treatment (cytoreductive surgery and adjuvant paclitaxel and platinum-based chemotherapy); however, most of them will recur [4, 5]. Subsequent treatment with second-line or third-line agents (after interim non-platinum therapy) results in less than 33% response rate due to the increase of resistance to these drugs [6–9]. The poor survival rate for women with platinum-resistant ovarian carcinomas demands alternative treatment strategies.
Platinum-based chemotherapy is still an effective treatment for ovarian cancer in spite of severe side effects and development of resistance associated with its use . Cis-diamminedichloroplatinum (II) (cisplatin) is a platinum-based compound that has clinical activity against a wide array of solid cancers including ovarian, testicular, bladder, colorectal, lung, and head and neck . DNA-damage response and mitochondrial apoptosis play a major role in cisplatin’s mode of action [12, 13]. In addition, cisplatin is known to cause oxidative stress  via generation of superoxide anions and hydroxyl radicals . Despite consistent initial responses, cisplatin treatment often results in the development of chemo-resistance, leading to therapeutic failure [10, 11]. The use of cisplatin is also limited by dose associated toxicity and side effects. Serious side effects that limit the dose of cisplatin include neurotoxicity and nephrotoxicity [11, 15]. In order to mitigate the side effects and resistance resulting from cisplatin-based chemotherapy, it is essential to investigate new drugs which are non-toxic and work in alternative/similar pathways to cisplatin, thus providing additional therapeutic options in ovarian cancer.
In recent years, a number of compounds have been explored in combination with cisplatin. Some of these include N-acetylcysteine , naltrexone , glutathione ester , vitamin E and losartan , melatonin , quercetin , metformin [22, 23], and rehmannia . However, none of these combinations were successful for clinical application. In the present study, we investigated the novel combination of cisplatin with Bithionol [2, 2′-Sulfanediylbis (4, 6-dichlorophenol)] (BT) as an alternate therapeutic strategy. BT is a Food and Drug Administration-approved antiparasitic agent that has been safely dosed in humans to be used orally as a second-line medication for the treatment of helminthic infections . Previously, we showed that BT exerts cytotoxic effects on a panel of ovarian cancer cell lines regardless of their cisplatin sensitivities . BT half maximal inhibitory concentrations (IC50) observed in several ovarian cancer cell lines were well below the reported clinically tolerable levels in humans. Our recent in vivo study did not demonstrate the anti-tumor potential of BT (pharmaceutical grade); however, lack of toxicity at any of the tested doses and the ability of BT to induce apoptosis still make BT a promising candidate to be utilized in therapeutics . To further explore the anti-tumor potential of BT, it is important to know the combined effects of BT with standard chemotherapeutic agent(s) such as cisplatin and paclitaxel. In this study, we assessed the antitumor efficacy of BT in combination with cisplatin using a panel of ovarian cancer cell lines such as OVACAR-3, SKOV-3 (Additional file 1) and the isogenic ovarian cancer cell lines pairs A2780 (cisplatin-sensitive) / A2780-CDDP (cisplatin-resistant) and IGROV-1 (cisplatin-sensitive) / IGROV-1CDDP (cisplatin-resistant). The primary objectives of this study are to determine the optimal combination of BT and cisplatin to achieve enhanced cytotoxic activity of both drugs and to understand the mechanism(s) of action of BT-cisplatin combination.
BT and cisplatin combinations were evaluated systematically for drug-ratio dependent interactions in vitro. The nature of the interactions between BT and cisplatin was evaluated by three different approaches – (1) sequential addition of drugs that involves pre-treatment with BT for 24 h followed by cisplatin addition (drugs in non-constant ratio), (2) simultaneous addition of both drugs in non-constant ratio and (3) simultaneous addition of drugs in constant ratio. The combination index was used to evaluate if the interactions are antagonistic, synergistic or additive.
Cisplatin and other anti-neoplastic agents exhibit cytotoxic effects via elevation of intracellular reactive oxygen species (ROS) that may contribute to their therapeutic effect. BT was shown to induce apoptosis via cell cycle regulation, ROS generation, NF-κB inhibition and autotaxin (ATX) inhibition. To investigate the molecular mechanism(s) of action of BT-cisplatin combination in ovarian cancer cells in vitro, we evaluated ROS generation, ATX inhibition, induction of apoptosis and expression of key apoptotic and cell cycle modulators.
Cell lines and chemicals
Isogenic ovarian cancer cell lines pairs, e.g., A2780 /A2780-CDDP and IGROV-1/, IGROV-1CDDP were received as a generous gift from Dr. Brodsky (Brown University, Providence, RI). The parental cell lines were purchased from Sigma and made resistant in vitro by continuous stepwise exposure to cisplatin to produce the corresponding cisplatin-resistant cell lines. All cell lines were maintained in DMEM media (Sigma) supplemented with 10% heat-inactivated FBS (Hyclone), 100 IU penicillin (Mediatech) and 100 μg/mL streptomycin (Mediatech). All cell lines were cultured at 37 °C in a humidified atmosphere at 5% CO2. The cisplatin-resistant variants A2780-CDDP and IGROV-1CDDP cells were treated with 3 μM cisplatin every third passage to maintain cisplatin resistance.
BT and cisplatin (Cis-diamminedichloroplatinum (II)) were purchased from Sigma (St Louis, MO). All primary antibodies were purchased from Cell Signaling Technologies, (Danvers, MA). PrestoBlue™ Cell Viability Reagent and ROS Dye - carboxy-H2DCFDA were purchased from Invitrogen (Carlsbad, CA).
Cell viability assay
Cell viability after drug(s) treatment was determined by Presto Blue cell viability reagent (Invitrogen) as descried previously . In brief, ovarian cancer cell lines (5 × 103 cells/well) were plated into 96-well plates (Corning, Inc., Corning, NY) and incubated overnight. Cells were treated with different concentrations of both drugs either alone or in combination and incubated for 48 h. BT was tested at concentrations ranging from 3.56 μM to 100 μM and cisplatin at concentrations between 1.57 and 200 μM. A minimum of 4–6 h prior to the end of treatment, presto blue reagent was added and incubated for 48 h followed by measurement of fluorescence (540 nm excitation/590 nm emissions). DMSO concentration was corrected to 1% in all wells. All treated cells were compared against control cells (considered as 100% viable) treated with 1% DMSO media. Data were expressed as mean ± SD of triplicate experiments.
In order to determine role of ROS in BT-cisplatin induced cytotoxicity, cell viability assays were performed in the presence the antioxidant ascorbic acid (AA). Cells were pretreated with 1 mM AA for 2 h prior to addition of drugs and further incubated for 48 h. Restoration of cell viability was analyzed.
Drug combination studies
To assess combination effects of BT with cisplatin, these drugs were combined in constant and non-constant ratios. In constant ratio combination, BT and cisplatin were combined at a fixed ratio based on the IC50 values of the individual drugs (i.e., concentrations causing 30–50% of cytotoxicity when these agents are used alone). Subsequently, this drug mixture was serially diluted to obtain different concentrations of the combination. The dose ranges selected for combination studies were 3.25 μM to 100 μM for BT and 1.56 μM to 200 μM for cisplatin. For non-constant ratio combination, BT and cisplatin were prepared at a series of concentrations that spans the dose–response curves for both drugs. Each concentration of BT was mixed with each concentration of cisplatin, thereby producing a matrix of multiple stock admixtures, containing both drugs together in solution at a variety of concentrations and ratios.
The nature of the interaction between BT and cisplatin was assessed using three different approaches: (1) simultaneous treatment with both drugs in non-constant ratio, where cells were treated with both BT and cisplatin simultaneously combined in a non-constant ratio; (2) simultaneous treatment with both drugs in constant drug ratio, where cells were treated with both BT and cisplatin simultaneously combined in a constant ratio and (3) pre-treatment with BT followed by addition of cisplatin in non-constant ratio, where cells were treated with different concentrations of BT for 24 h after which BT was removed and cisplatin was added for another 24 h. Here also each concentration of BT pre-treatment is followed by each concentration of cisplatin thereby producing a matrix of multiple stock admixtures (non-constant ratio).
The tumor growth inhibition obtained for BT-cisplatin combination over a range of concentrations was compared to that obtained for the individual drugs, and a measure of the synergy between the two drugs, referred to as the combination index (CI), was calculated using a median-effect mathematical algorithm . CalcuSyn (BioSoft) was used to calculate CI values for drug combinations. A drug combination is synergistic if its CI value is significantly below 1; the combination is additive where the CI is between 0.9 and 1.0; and the combination is antagonistic as indicated by CI values above 1.0.
Caspase 3/7 assay
Caspase 3/7 activity was measured using Caspase-Glo 3/7 assay kit from Promega, following the manufacturer’s instructions. Briefly, 10 × 103 cells were plated per well of the 96-well plate and treated with BT and cisplatin either alone or in combination. Following treatment, Caspase-Glo 3/7 reagent was added and incubated for 30 min. at room temperature. The luminescence intensity was measured using a luminometer (luminoskan, Thermo Scientifics). Drug-treated cells were compared against cells treated with 1% DMSO media (controls). Data were expressed as mean ± SD of triplicate experiments.
Apoptosis detection via Hoechst staining
NucBlue Live Cell Stain (Hoechst 33342; Invitrogen, Carlsbad, CA) was used to morphologically assess nuclear condensation indicative of apoptosis. This qualitative test was performed as described previously [26, 29]. In brief, cells (1 × 105 cells) were seeded into 12-well plate and treated with BT and cisplatin either alone or in combination for 24 h. Following treatment, cells were washed, stained with Hoechst stain (2 drops/mL of media) for 15 min. at 25 °C and observed under a fluorescent microscope. Representative images were taken with an inverted microscope (Olympus H4-100, CCD camera) and 20× objective.
Apoptosis quantification via TUNEL assay
DNA fragmentation was detected using the TiterTACS® 2 TdT in Situ Colorimetric Apoptosis Detection Kit (Trevigen, Gaithersburg, MD) following the manufacturer’s instructions. Briefly, cells were seeded at a density of 3 × 104 cells/well, into 96-well flat bottom plates and incubated overnight. Cells were treated with BT and cisplatin either alone or in combination for 24 h. After treatment with drugs, cells were washed and fixed. Subsequently, labeled nucleotides were added and measurements were performed with HRP – HRP substrate (TACS-Sapphire) system. The absorbance was measured at 450 nm using a microplate reader, Multiskan (Thermo Scientifics).
Estimation of reactive oxygen species (ROS) production
Hydrogen peroxide, hydroxyl radicals and peroxy radicals were detected via carboxy-H2DCFDA using flow cytometry as described previously . Briefly, cells (1 × 106) were seeded in 100 mm2 culture dishes and treated with BT and cisplatin either alone or in combination for 24 h. After treatment, the cells were washed once with PBS, collected by centrifugation after trypsinization, re-suspended in fresh PBS and incubated with 5 μM 5,6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA, C400, Invitrogen, Eugene, Oregon, USA) for 30 min at 37 °C. The cells were washed twice with PBS, re-suspended in an equal volume of PBS and fluorescence measured with flow cytometry. Data was acquired on a BD Accuri C6 flow cytometer and analyzed using Accuri C6 software (BD Immunocytometry-Systems, San Jose, CA). Twenty thousand cells were analyzed for each sample. Subsequent cell viability assay with AA pretreatment was performed.
Western blot analysis
Western blotting was performed to evaluate expression of key modulators of apoptosis such as cleaved PARP, XIAP, bcl-2 and bcl-xL. Key cell cycle regulators such as p21 and p27 were also assessed by western blotting. Cell seeding, cell lysis and western botting were done as described previously . In brief, cells were treated with BT and cisplatin either alone or in combination. After treatment for 24 h, cells were harvested and lysed in cell extraction buffer (Invitrogen, Carlsbad, CA) containing 10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate protease inhibitor cocktail and PMSF. Cell lysates were subjected to western blotting. After overnight incubation with respective primary antibodies at 4 °C, and subsequent incubation with appropriate secondary antibodies (Licor), the proteins on the blots were detected using a Licor image analyzer.
Autotaxin (ATX) assay
The phosphodiesterase activity of ATX was measured as described previously . In brief, cells were treated with BT and cisplatin either alone or in combination. Following treatment, cell-free supernatants were collected. The concentration of ATX was normalized with respect to the cell mass of samples in each well. To estimate ATX, 100 μL cell-free culture media were incubated with 100 μL substrate containing p-nitrophenylphosphonate (pNppp) at a final concentration of 5 mM prepared in 50 mM Tris–HCl buffer, pH 9.0. After 30 min incubation at 37 °C, the reaction was stopped by the addition of 100 μL of 0.1 M NaOH solution. The reaction product was measured by reading the absorbance at 410 nm. ATX inhibition of treated cells was calculated as the percentage of ATX activity in comparison with untreated cells.
Comparisons between cisplatin treated and BT/cisplatin combination treated groups were performed by Student’s t–test. The significance level was set at p < 0.05.
BT-cisplatin combination cytotoxicity studies
The objective of the present study is to investigate the effects of BT-cisplatin combination in ovarian cancer cell lines with special focus on cisplatin-sensitive and cisplatin-resistant isogenic pair of cell lines. Cells were exposed to different concentrations of BT and cisplatin either alone or in combination. The combination index (CI) value, calculated according to Chou’s methods , was used to determine the nature of the interaction between BT and cisplatin. The CI results are shown as a heat map where the green color indicates synergism (CI value < 1), the yellow color indicates additive effect (CI = 1) and the red color indicates antagonism (CI > 1). Our previous results have shown that both BT and cisplatin induced cell death in a time and dose dependent manner when added alone for 48 h (data not shown). BT-cisplatin combination-induced cytotoxicity profiles on individual ovarian cancer cell lines are described below:
A2780 (cisplatin-sensitive) and A2780-CDDP (cisplatin-resistant) isogenic pair
When A2780 cells were pretreated with BT followed by cisplatin addition, there was synergy only at lower BT (3.25 and 6.25 μM) and cisplatin (1.56–6.25 μM) concentrations (Fig. 1a). At higher concentrations of cisplatin, an additive effect was observed but only lower BT concentrations (3.25–6.25 μM). Higher BT concentrations were antagonistic to cisplatin action (CI >1; represented as red). Similarly, when cells were treated with BT and cisplatin simultaneously, antagonism was observed at most drugs ratios. Synergistic effect was observed only at lower BT (3.25 and 6.25 μM) and cisplatin (1.56–6.25 μM) concentrations. As shown in Fig. 1b, combination with BT (12.5 μM) reduced the cytotoxic potential of cisplatin by 4–12% at lower cisplatin concentrations (1.56–12.5 μM). At synergistic drug ratios, combination with 6.25 μM BT enhanced cytotoxic potential of cisplatin by 4 to 33% at lower cisplatin concentrations (1.56–12.5 μM). In summary, BT and cisplatin were in general antagonistic irrespective of the drug sequence employed. However, synergy was observed only at lower BT and cisplatin concentrations, when added simultaneously or when pretreated with BT.
In contrast to A2780 (cisplatin-sensitive), in A2780-CDDP (cisplatin-resistant), BT was synergistic to cisplatin action at most of the drug ratios either when cells were pre-treated with BT or when both BT and cisplatin were added simultaneously (Fig. 1c). At higher BT concentrations, additive effect was observed. When added simultaneously, at synergistic drug ratios, combination with 12.5 μM BT enhanced cytotoxic potential of cisplatin by 66 to 86% at cisplatin concentrations of 1.56–50 μM (Fig. 1d). The synergistic action of BT and cisplatin on cisplatin-resistant cell lines was independent of the drug sequence employed.
IGROV-1 (cisplatin-sensitive) and IGROV-1-CDDP (cisplatin-resistant) isogenic pair
When IGROV-1 cells were pretreated with BT followed by cisplatin addition, antagonism was observed at most drugs ratios (Fig. 2a). Synergy only occurred at higher cisplatin (100–200 μM) concentrations, which has no physiological significance. Similarly, when these cells were treated with BT and cisplatin simultaneously, BT was synergistic to cisplatin action only at the lowest BT (3.25 μM) and cisplatin concentrations ranging 1.56 to 12.5 μM. At higher concentrations of cisplatin, an additive effect was observed but only at lowest BT concentration (3.25 μM). Higher BT concentrations were antagonistic to cisplatin action. As shown in Fig. 2b, combination with BT (50 μM) reduced the cytotoxic potential of cisplatin by 6–14% at lower cisplatin concentrations (1.56–25 μM). At synergistic drug ratios, combination with 3.25 μM BT enhanced cytotoxic potential of cisplatin by 2 to 26% at lower cisplatin concentrations (1.56–12.5 μM). In summary, the actions of BT and cisplatin on IGROV-1 cells were, in general, antagonistic. However, some synergy was observed at lowest BT and cisplatin concentrations only when pretreated with BT.
Interestingly, in the IGROV-1-CDDP (cisplatin-resistant) cell line, BT was synergistic to cisplatin action in a drug concentration dependent manner, either when cells were pre-treated with BT or when both BT and cisplatin were added simultaneously. Synergy was observed at low (3.25 μM) or towards higher (50 and 100 μM) concentrations of BT when combined with cisplatin at all concentrations (Fig. 2c). When added simultaneously, at synergistic drug ratios, combination with 50 μM BT enhanced the cytotoxic potential of cisplatin by 36 to 80% at cisplatin concentrations of 1.56–25 μM (Fig. 2d).
OVCAR-3 and SKOV-3
In these cell lines, BT and cisplatin act in general antagonistic, however, synergy was observed at very narrow drugs ratios with slightly better response when both drugs were added simultaneously (data attached as Additional file 1: Figure S1).
In summary our studies performed using isogenic pairs of cell lines show that BT and cisplatin are in general synergistic in cisplatin-resistant cell lines and antagonistic in cisplatin-sensitive cell lines. Synergy was observed when added simultaneously or when pretreated with BT. These results further support the fact that BT sensitizes cisplatin-resistant cells to respond better to cisplatin treatment.
BT inhibits apoptosis when used in combination with cisplatin
To determine the mechanisms underlying antagonism or synergism between BT and cisplatin, we tested the effect of BT on cisplatin-induced apoptosis in cisplatin-sensitive and cisplatin-resistant isogenic pairs of cell lines. Qualitative morphological assessment was performed by nuclear (Hoechst) staining. As shown in Fig. 3a and c, vehicle-treated (control) cells stained very faintly while treated cells had a stronger blue fluorescence indicative of highly condensed chromatin, characteristic of apoptotic cells. Cisplatin-sensitive cells (A2780 and IGROV-1) treated with either BT or cisplatin alone showed higher fluorescence than those treated with BT-cisplatin combination. In contrast, cisplatin-resistant variants (A2780-CDDP and IGROV-1-CDDP) treated with BT-cisplatin combination displayed higher fluorescence than the same cell lines treated with either BT or cisplatin alone. Both isogenic pairs of cell lines exhibited similar profiles. The extent of apoptosis expressed as percentage of DNA fragmentation was quantified using the TUNEL assay. As shown in Fig. 3b and d, in both isogenic cell line pairs, cisplatin-sensitive cell lines showed considerably higher DNA fragmentation when treated with cisplatin or BT alone as compared to BT-cisplatin combination (simultaneous) treatment. A2780 cells treated with 12.5 μM BT or 12.5 μM cisplatin alone exhibited 17 ± 2 and 28 ± 3% of DNA fragmentation, respectively. When treated with both drugs in combination (simultaneously or pretreated with BT followed by cisplatin), the percentage of DNA fragmentation decreased to 15 ± 1 and 13 ± 1% respectively (Fig. 3b). For A2780-CDDP cells, treatment with 12.5 μM BT caused 13 ± 2.9% DNA fragmentation. No significant DNA fragmentation was observed when these cisplatin resistant cells were treated with 12.5 μM cisplatin alone. Upon combination, the percentage of DNA fragmentation increased significantly to 81 ± 3.76 and 75 ± 2%, respectively, when added simultaneously or pretreated with BT followed by cisplatin (Fig. 3b). IGROV-1 cells treated with 50 μM BT or 12.5 μM cisplatin alone showed 22 ± 2 and 38 ± 3% of DNA fragmentation respectively. When these cells were treated with both drugs in combination (simultaneously or pretreated with BT followed by cisplatin), the percentage of DNA fragmentation decreased to 11 ± 1 and 6 ± 1% respectively (Fig. 3d). In the case of IGROV-1-CDDP cells, treatment with 50 μM BT caused 31 ± 2.9% DNA fragmentation. No significant DNA fragmentation was observed when these cells where treated with 12.5 μM cisplatin alone. Upon drug combination, the percentage of DNA fragmentation increased significantly to 61 ± 3.76 and 59 ± 2% respectively, when drugs were added simultaneously or pretreated with BT followed by cisplatin (Fig. 3d).
Effect of BT-cisplatin combination on apoptotic markers
In order to confirm the results obtained with DNA fragmentation studies, we also assessed other apoptotic markers. As shown in Fig. 4a and b, significant reduction of caspases activity was observed when cisplatin-sensitive variants of isogenic cell line pairs, such as A2780 and IGROV-1, were treated with BT and cisplatin in combination, as compared to when treated with either of the drugs alone. In contrast, cisplatin-resistant variants of these isogenic cell line pairs (A2780-CDDP and IGROV1-CDDP) showed increased caspase 3/7 activity when treated with both drugs in combination as compared to when treated with either of the drugs alone (Fig. 4a and b).
Similarly, increased PARP protein cleavage product (85 kDa, 1 fragment) was observed in cisplatin-sensitive cell lines such as A2780 and IGROV, when treated with either of the drugs alone (Fig. 4c and d). However BT-cisplatin combination reduced the expression of cleaved PARP. In contrast, cisplatin-resistant variant of these cell lines (A2780-CDDP and IGROV1-CDDP) showed increased PARP protein cleavage product when treated with both drugs in combination as compared to when treated with either of BT or cisplatin alone.
To confirm that the potentiation/attenuation of cisplatin-induced cytotoxicity by BT treatment is accompanied by changes in the expression of key regulators of apoptosis, we also assessed the expression of XIAP, bcl-2 and bcl-xL. As shown in Fig. 4c and d, down regulation of XIAP, Bcl-2, bcl-xL was observed in cisplatin-sensitive cell lines (A2780 and IGROV-1) when treated with either of the drugs alone. However, treating the cells with BT-cisplatin combination reduced cisplatin-induced apoptotic effects as the expressions of XIAP, bcl-2 and bcl-xL increased. In contrast, cisplatin-resistant cell lines displayed significant down regulation of XIAP, bcl-2, bcl-xL when treated with BT-cisplatin combination as compared to either agent alone.
Our results suggest that BT significantly inhibits apoptosis when added in combination with cisplatin in cisplatin-sensitive cell lines (A2780 and IGROV-1) whereas it increases apoptosis in cisplatin-resistant variants (A2780-CDDP and IGROV1-CDDP). Furthermore, these results suggest that cisplatin in combination with BT caused down-regulation of key survival proteins such as XIAP, Bcl-2, and bcl-xL compared to either of the drugs alone, thus resulting in greater apoptosis/cytotoxicity. These results show that the nature of drug interactions depends on the extent of apoptosis that occurs when cells are treated in combination. Synergistic interaction enhanced apoptosis whereas antagonistic interactions reduced the extent of apoptosis.
Effect of BT-cisplatin combination with key regulators of cell cycle
We assessed the expression of the cell cycle regulators P27 (kip1) and p21 in order to understand their role in causing antagonistic or synergistic effects of BT and cisplatin combination. Figure 4c and d show that BT and cisplatin both enhanced expression of P27 (kip1) and p21 when used alone. When cisplatin and BT were used in combination, the expression of P27 and P21 was reduced in cisplatin-sensitive cell lines (A2780 and IGROV-1) and enhanced in cisplatin-resistant cell lines (A2780-CDDP and IGROV1-CDDP), compared to cisplatin or BT treatments alone. These results are consistent with the cytotoxicity data, where combination treatment potentiated cytotoxicity in cisplatin-resistant cell lines and attenuated it in cisplatin-sensitive cell lines.
BT potentiates cisplatin-induced apoptosis by increasing ROS generation in cisplatin-resistant cell lines whereas it reduces ROS in cisplatin-sensitive cell lines
We measured ROS levels to examine whether ROS are involved in the synergistic/antagonistic interaction between cisplatin and BT. As shown in Fig. 5a and b, treatment with BT or cisplatin alone lead to an increase in ROS generation evidenced by a shift in fluorescence peak (consistent with previous studies). Compared to BT, cisplatin caused greater generation of ROS in most of the cell lines. Our results further show that combinational treatment with cisplatin and BT generated more ROS relative to either of the drugs alone in cisplatin-resistant cell lines whereas it decreased ROS generation in cisplatin-sensitive cell lines. These results imply significance of ROS in the cytotoxic effects of BT-cisplatin combination. In order to confirm the role of ROS generation in antagonistic or synergistic interactions between BT and cisplatin, we tested cell viability in the presence or absence of the antioxidant ascorbic acid (AA). As shown in Fig. 5c and d, combinational treatment with cisplatin and BT in the presence of 1 mM AA restored only 10–13% viability in cisplatin-sensitive cell lines A2780 and IGROV-1. Interestingly, cisplatin-resistant variants displayed greater restoration of cell viability (75 and 85% viability restoration in A2780-CDDP and IGROV-1-CDDP, respectively). Treatment with 1 mM AA did not cause any loss in cell viability in any of the cell lines. These results implicate ROS-mediated cytotoxicity in cisplatin-resistant cell lines when treated with cisplatin and BT in combination. Lack of significant restoration of cell viability in cisplatin-sensitive cell lines implicates minimal contribution of ROS upon combination treatment.
Effect of BT-cisplatin combination on ATX
ATX inhibition was considered major mechanism of action of BT. In order to determine if ATX inhibition potential of BT has any contribution to the synergy observed in cisplatin-resistant cell lines, we assessed the ATX levels in cell lysates treated with either of the drugs alone or in combination. As shown in Fig. 6a, no significant changes in ATX were observed when A2780 or A2780-CDDP cells were treated with either 12.5 μM BT or 12.5 μM cisplatin alone. No significant difference was seen when treated with BT-cisplatin combination also. Figure 6b shows that 12.5 μM cisplatin did not cause significant changes in ATX levels in either IGROV-1 or IGROV1-CDDP cell lines (94 ± 3 and 92 ± 5%, respectively). In contrast, treatment with 50 μM BT caused a significant decrease in ATX in both cell lines (65 and 68% respectively). However, when added in combination with cisplatin, no significant differences in ATX levels were observed as compared to cisplatin alone (89 ± 5 and 88 ± 5%, respectively). These results confirm lack of ATX involvement in drug interactions effects.
Treatment with of ovarian cancer with a single anticancer agent often cannot provide a satisfactory therapeutic effect in recurrent patients due to drug resistance and dose-limiting side effects . Therefore, it is essential to find novel compounds/drugs that enhance the therapeutic efficiency of cisplatin, allowing for the use of lower doses and therefore reducing its toxic side effects. In this study we evaluated BT - cisplatin combination as a novel treatment for ovarian cancer.
Previously, we showed that BT exerts cytotoxic effects on a panel of ovarian cancer cell lines regardless of their cisplatin sensitivities. BT was shown to induce apoptosis both in vitro and in vivo [26, 27]. Our in vitro studies suggested that BT’s mechanism(s) of action involve cell cycle regulation, ROS generation, NF-κB inhibition and ATX inhibition. In cisplatin-resistant cell lines, ROS generation seems to be the major mechanism of BT cytotoxicity . Additionally, our recent in vivo study showed that pharmaceutical grade BT was well tolerated at relatively high concentrations without any toxic side effects although an anti-tumor effect was not observed at the doses tested . Any drug that is known to cause cell cycle mediated apoptosis, ROS generation or NF-κB inhibition without any toxic effects is considered an ideal candidate for combination with cisplatin for treatment of ovarian cancer. Consequently, we chose BT to be tested in combination with standard chemotherapeutic agent(s) such as cisplatin and paclitaxel.
Combination chemotherapy has been in practice for cancer treatments for many decades. The principle underlying this approach so far has been to administer each drug at their maximum tolerated dose (MTD) to achieve maximum therapeutic efficiency. However, clinical data suggested that this approach failed to exploit the full potential of many therapeutic drugs used in combinations and may have resulted in multidrug resistance in tumor cells. The major reason for such a phenomenon is exposure of tumor cells to drugs at antagonistic ratios or concentrations. The nature of the interactions (synergism or antagonism) of anticancer agent combinations against tumor cells in vitro depends on the concentrations of the individual drugs. Ratiometric dosing is an approach to develop drug combinations based on drug ratio–dependent synergy. It is essential to determine optimal drug concentrations/ratios to obtain synergy so as to prevent the exposure of cells to antagonistic ratios. In our study, we employed both constant and non-constant drugs ratios to understand the nature of interactions between our two chosen drugs. BT and cisplatin combinations were evaluated systematically for concentration-dependent interactions in in vitro using the isogenic ovarian cancer cell lines pairs A2780 (cisplatin-sensitive) / A2780-CDDP (cisplatin-resistant) and IGROV-1 (cisplatin-sensitive) / IGROV-1CDDP (cisplatin-resistant). This study shows the differential response of cisplatin-sensitive and cisplatin-resistant cell lines to BT/cisplatin combination treatment. In cisplatin-sensitive cell lines, BT/cisplatin combination was antagonistic at most drug concentrations; however the use of lower concentrations of BT and cisplatin resulted in synergy. In contrast, when tested on cisplatin-resistant cell lines, these agents were synergistic at most of the ratios/concentrations. Our results show that synergy is highly dependent on the concentration of the drugs used. Optimal response was observed when BT and cisplatin were combined at lower concentrations in a non-constant ratio. With regard to sequence of drugs applied, simultaneous treatment with BT and cisplatin appears to be a better option as compared to pretreatment with BT followed by cisplatin treatment. These results support the fact that BT sensitizes cisplatin-resistant cells to respond better to cisplatin treatment.
As reported by many, drug ratios identified as antagonistic in vitro provide inferior therapeutic activity in vivo compared with a synergistic drug ratio. Hence, it is very important to determine optimal drug ratios and then translate in vitro information on drug ratio-dependent synergy to in vivo efficacy using various drug delivery technologies. Combination drug delivery systems such as polymeric nanoparticles, dendrimers, liposomes, and water-soluble polymer-drug conjugates can be used to obtain synergistic anticancer effects while reducing concentration-related toxicity of the individual drugs [31, 32].
In addition to determining an optimal drug combination, the aim of this study was to investigate molecular mechanism(s) of action of BT/cisplatin combination in ovarian cancer cells in vitro. Oxidative stress and apoptosis are often the main factors contributing to the anticancer effects of drugs that target DNA [33, 34]. Since both BT and cisplatin are known to induce DNA damage, we evaluated induction of apoptosis, ROS generation, and expression of key apoptotic and cell cycle modulators as possible mechanisms of action for BT-cisplatin combination. The fact that BT has been reported to inhibit ATX activity prompted us to determine the effect of BT/cisplatin combination on ATX levels as well [26, 35, 36]. Surprisingly, when BT was added in combination with cisplatin, no significant differences in ATX levels were observed for any paired cell lines (IGROV-1 and A2780). We surmise that ATX inhibition does not play a critical role in the mechanism of action of the BT/cisplatin combination in these cell lines.
There is a consensus pointing to apoptosis as the principal mechanism by which chemotherapy agents induce cancer cell death. The majority of anticancer drugs induce apoptosis via the intrinsic (mitochondrial - cytochrome c/Apaf-1/caspase-9) pathway [37, 38]. Mitochondria are known to be both a source and a target of ROS. Disruption of mitochondrial potential can lead to oxidation of mitochondrial pores by ROS, resulting in release of cytochrome C into the cytosol . The formation of an apoptosome containing cytochrome C, apoptotic protease activating factor-1 (Apaf-1) and dATP is followed by procaspase-9 recruitment and activation. Subsequently, Caspase-9 activates caspases −3 and −7 which execute the final steps of apoptosis. Consistent with previous reports on BT and cisplatin [11, 26, 27], our study shows that BT and cisplatin, when used alone, induce DNA fragmentation indicative of apoptosis. Furthermore, in cisplatin-sensitive variants, cells treated with individual drugs alone displayed higher degrees of apoptosis as compared to BT-cisplatin combination. In contrast, cisplatin-resistant variants treated with BT-cisplatin combination exhibited more apoptosis than those treated with either cisplatin or BT alone. In order to confirm the results obtained with DNA fragmentation assays, we also measured other markers of apoptosis. BT/cisplatin combination treatment reduced caspases activity and cleaved PARP in cisplatin-sensitive cell lines. In contrast, increased caspases 3/7 activity and cleaved PARP was observed in cisplatin-resistant variants of these isogenic cell line pairs treated with both drugs in combination as compared to when treated with either of the drugs alone. The nature of drug interactions depends on the extent of apoptosis that occurs when the drugs are used in combination. Synergistic interaction enhanced apoptosis whereas antagonistic interactions reduced extent of apoptosis.
Several compounds have been shown to alleviate cisplatin-induced nephrotoxicity through the translational regulation of Bcl-2 [40, 41]. Bcl-2 overexpression in conjunction with p53 has been found in fresh ovarian tissue biopsies . Bcl-2 has been reported to protect ovarian cancer cells from drug-induced apoptosis, contributing to chemo-resistance [42, 43]. Inhibition of bcl-xL may increase sensitivity to chemotherapy agents such as carboplatin . In this context, we also assessed the expression of pro-survival factors such as XIAP, bcl-2 and Bcl-xL. We found that in cisplatin-sensitive cell lines, BT/cisplatin combination reduced cisplatin-induced apoptotic effects as increased expressions of XIAP, bcl-2 and bcl-xL was observed. In contrast, cisplatin-resistant cell lines showed significant down regulation of XIAP, bcl-2, bcl-xL when treated with BT/cisplatin combination as compared to either agent alone, thus resulting in greater apoptosis/cytotoxicity. These observations implicate BT/cisplatin combination may be a useful approach in treating cisplatin-resistant ovarian cancers.
ROS are byproducts of normal cellular metabolism which play a crucial role in cell regulation and signal transduction . Many studies have shown that cancer cells display elevated ROS levels compared to non-cancerous cells; thus, further ROS increase would make cancer cells more susceptible to oxidative damage (reviewed in ). Indeed, a number of common chemotherapeutic drugs including daunorubicin, cyclophosphamide, Taxol and cisplatin have been proposed to induce apoptosis through the generation of an excess amount of ROS [47–49]. However, prolonged exposure to cisplatin may reduce cellular levels of ROS resulting in chemo-resistance. Enhanced elevation of cellular ROS level by an exogenous ROS source in combination with cisplatin may re-sensitize drug-resistant cancer cells . We used this approach to augment efficiency of cisplatin in cisplatin-resistant cells by combining cisplatin with BT. Previously, generation of ROS has been established as one of the underlying mechanisms of both BT and cisplatin cytotoxic activity [26, 51, 52]. Consistent with these previous reports, our study shows that treatment with either BT or cisplatin generated ROS, although ROS concentration was greater in cisplatin treated cells. Combination of cisplatin with BT further enhanced ROS production. Blocking ROS production by addition of antioxidant ascorbic acid showed a complete remission of cell death in cisplatin-resistant cells treated with BT/cisplatin suggesting that ROS production is the major mechanism of cell death for BT-cisplatin combination, thus overcoming cisplatin resistance. Our results show that BT/cisplatin combination potentiated cisplatin induced cytotoxicity by augmenting ROS accumulation and consequently activated pro-apoptosis pathways, especially in cisplatin-resistant cell lines.
Platinum derivatives have previously been shown to increase the expression of important cell cycle regulatory proteins such as p27 Kip1 and p21 Waf1/Cip1, leading to cell cycle inhibition [53, 54]. Similarly, BT was shown to cause increased expression of proteins P27 (kip1) and p21 in ovarian cancer cell lines in in vitro . We assessed the expression of P27 (kip1) and p21 in order to understand the role of these cell cycle regulators in causing antagonism or synergy of cisplatin and BT combination. Our results suggest that BT reduced the magnitude of cisplatin-induced cell cycle arrest by inhibiting P27 (kip1) and p21 expression in cisplatin-sensitive cell lines whereas it enhanced their expression in cisplatin-resistant cell lines. With P27 (kip1) and p21 being key inhibitors of cell cycle, our results are consistent with the cytotoxicity data where BT-cisplatin combination treatment potentiated and attenuated cytotoxicity in cisplatin-resistant and cisplatin-sensitive cell lines, respectively.
It is known that the major drawback of current cancer chemotherapy treatments is that the use of different drugs at high doses results in undesired toxicity, drug resistance and lack of expected efficacy (possibly as a consequence of antagonistic interactions between the drugs used). As reported in this study, drugs can be synergistic at certain ratios and antagonistic at other ratios implying the need to administer them at optimal doses. Therefore, there is a need to optimize drug ratios for every combination of drug used. Our results show that the use of cisplatin and BT at lower doses enhanced the efficacy of both drugs in most ovarian cancer cell lines tested. When used in combination with BT, cisplatin can be administered at lower doses, eliminating undesired side effects without compromising its efficacy. In this context, our study provides very significant systematic evaluation of BT-cisplatin interactions for possible application in drug/cisplatin resistance ovarian cancer scenarios.
Our results show that BT and cisplatin can be synergistic at certain ratios and antagonistic at other ratios implying the need to administer them at optimal doses. When used at optimal concentrations, BT/cisplatin combination potentiated cisplatin cytotoxicity by increasing the accumulation of ROS and consequently activating pro-apoptotic pathways in cisplatin-resistant cell lines. Our results suggest that repurposing of BT to be used in combination with cisplatin represents an attractive and innovative approach to enhance/restore chemosensitivity of ovarian cancer to cisplatin. Further in vivo experiments may further contribute to our understanding and confirm the therapeutic potential of BT for patients with ovarian cancer.
- IC50 :
Half maximal inhibitory concentration
- IGROV-1CDDP / A2780- CDDP:
Cisplatin-resistant variants of IGROV-1 and A2780
Nuclear factor kappa B
Reactive oxygen species
X-linked inhibitor of apoptosis
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
Herzog TJ. The current treatment of recurrent ovarian cancer. Curr Oncol Rep. 2006;8(6):448–54.
Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502–16.
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6.
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699–708.
Kikuchi Y. The mechanism of cisplatin-resistance in ovarian cancer. Hum Cell. 2001;14(2):115–33.
Leitao MM, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, Venkatraman E, Spriggs DR. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol. 2003;91(1):123–9.
Lambert HE, Gregory WM, Nelstrop AE, Rustin GJ. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer. 2004;14(5):772–8.
Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm (Weinheim). 2007;340(3):117–26.
Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs. 2010;19(11):1339–54.
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.
Jamieson ER, Lippard SJ. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev. 1999;99(9):2467–98.
Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001;67:93–130.
Wozniak K, Czechowska A, Blasiak J. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. Chem Biol Interact. 2004;147(3):309–18.
El-Awady E-S, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol. 2011;650(1):335–41.
Lorito G, Hatzopoulos S, Laurell G, Campbell KC, Petruccelli J, Giordano P, Kochanek K, Sliwa L, Martini A, Skarzynski H. Dose-dependent protection on cisplatin-induced ototoxicity - an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model. Med Sci Monit. 2011;17(8):BR179–186.
Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood). 2011;236(7):883–95.
Campbell KC, Larsen DL, Meech RP, Rybak LP, Hughes LF. Glutathione ester but not glutathione protects against cisplatin-induced ototoxicity in a rat model. J Am Acad Audiol. 2003;14(3):124–33.
Nematbakhsh M, Ashrafi F, Safari T, Talebi A, Nasri H, Mortazavi M, Khazaei M, Baradaran-Mahdavi MM. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol. 2012;25(3):410–7.
Tuncer S, Dalkilic N, Akif Dunbar M, Keles B. Comparative effects of α lipoic acid and melatonin on cisplatin-induced neurotoxicity. Int J Neurosci. 2010;120(10):655–63.
Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Perez-Barriocanal F, Morales AI, Lopez-Novoa JM. Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol Dial Transplant. 2011;26(11):3484–95.
Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol. 2011;121(3):492–8.
Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011;13(5):483–91.
Yu HH, Seo SJ, Kim YH, Lee HY, Park RK, So HS, Jang SL, You YO. Protective effect of Rehmannia glutinosa on the cisplatin-induced damage of HEI-OC1 auditory cells through scavenging free radicals. J Ethnopharmacol. 2006;107(3):383–8.
Bacq Y, Besnier JM, Duong TH, Pavie G, Metman EH, Choutet P. Successful treatment of acute fascioliasis with bithionol. Hepatology. 1991;14(6):1066–9.
Ayyagari VN, Brard L. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action. BMC Cancer. 2014;14:61.
Ayyagari VN, Johnston NA, Brard L. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer. Anticancer Drugs. 2016;27(6):547–59.
Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–6.
Kasibhatla S, Amarante-Mendes GP, Finucane D, Brunner T, Bossy-Wetzel E, Green DR. Detection of phosphatidylserine externalization during apoptosis. CSH Protoc. 2006(3): pii: pdb.prot4494.
Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011;71(11):1397–412.
Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818–22.
Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007;9(2):E128–147.
Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med. 2001;7(10):1111–7.
Kim KK, Kawar NM, Singh RK, Lange TS, Brard L, Moore RG. Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines. Gynecol Oncol. 2011;122(1):183–9.
Braddock D. Small molecule inhibitors of autotaxin, and methods of use. Application WO2009151644 A2. USA: Yale University; 2009. This patent is notable as one of only two that include demonstration in vivo of anti- cancer activity of an ATX inhibitor.
Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther. 2008;7(10):3352–62.
Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256(1):42–9.
Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. Bioessays. 2000;22(11):1007–17.
Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B, Kroemer G. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 1995;182(2):367–77.
Liu L, Yang C, Herzog C, Seth R, Kaushal GP. Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochem Pharmacol. 2010;79(2):137–46.
Gao JJ, Cai GY, Ning YC, Liu L, Yang JR, Dong D, Fu B, Lu Y, Cui SY, Chen XM. DAP5 ameliorates cisplatin-induced apoptosis of renal tubular cells. Am J Nephrol. 2012;35(5):456–65.
Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 1995;11(7):1217–28.
Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996;56(9):2178–84.
Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007;13(23):7191–8.
Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol. 2000;279(6):L1005–1028.
Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579–91.
Kim JS, Lee JH, Jeong WW, Choi DH, Cha HJ, Kim DH, Kwon JK, Park SE, Park JH, Cho HR, et al. Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspase-independent apoptosis in human head and neck squamous carcinoma cells. Int J Cancer. 2008;122(3):672–80.
Mansat-de Mas V, Bezombes C, Quillet-Mary A, Bettaïeb A, D’orgeix AD, Laurent G, Jaffrézou JP. Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol. 1999;56(5):867–74.
Tsai-Turton M, Luong BT, Tan Y, Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci. 2007;98(1):216–30.
Maiti AK. Gene network analysis of oxidative stress-mediated drug sensitivity in resistant ovarian carcinoma cells. Pharmacogenomics J. 2010;10(2):94–104.
Meshkini A, Yazdanparast R. Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells. Exp Toxicol Pathol. 2012;64(4):357–65.
Berndtsson M, Hägg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer. 2007;120(1):175–80.
Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res. 2000;60(19):5390–4.
He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer. 2006;95(11):1514–24.
Research reported in this manuscript was supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award number P20CA192987 (LB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
VA, TS and PD performed experimental procedures; VA and LB are responsible for study design and interpretation of results. VA, PD and LB are responsible for writing of manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Not applicable (this research does not involve participation of human subjects).
Ethics approval and consent to participate
No human subjects were involved in this research.
About this article
Cite this article
Ayyagari, V.N., Hsieh, T.J., Diaz-Sylvester, P.L. et al. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines. BMC Cancer 17, 49 (2017). https://doi.org/10.1186/s12885-016-3034-2
- Drug combination
- Ovarian cancer cell lines
- Reactive oxygen species